Plasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer's disease.
Alzheimer’s disease
Apolipoprotein E
Cholesterol efflux
High-density lipoproteins
Lecithin:cholesterol acyltransferase
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
20 05 2023
20 05 2023
Historique:
received:
15
03
2023
accepted:
06
05
2023
medline:
22
5
2023
pubmed:
21
5
2023
entrez:
20
5
2023
Statut:
epublish
Résumé
The purpose of this study was to evaluate cholesterol esterification and HDL subclasses in plasma and cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients. The study enrolled 70 AD patients and 74 cognitively normal controls comparable for age and sex. Lipoprotein profile, cholesterol esterification, and cholesterol efflux capacity (CEC) were evaluated in plasma and CSF. AD patients have normal plasma lipids but significantly reduced unesterified cholesterol and unesterified/total cholesterol ratio. Lecithin:cholesterol acyltransferase (LCAT) activity and cholesterol esterification rate (CER), two measures of the efficiency of the esterification process, were reduced by 29% and 16%, respectively, in the plasma of AD patients. Plasma HDL subclass distribution in AD patients was comparable to that of controls but the content of small discoidal preβ-HDL particles was significantly reduced. In agreement with the reduced preβ-HDL particles, cholesterol efflux capacity mediated by the transporters ABCA1 and ABCG1 was reduced in AD patients' plasma. The CSF unesterified to total cholesterol ratio was increased in AD patients, and CSF CER and CEC from astrocytes were significantly reduced in AD patients. In the AD group, a significant positive correlation was observed between plasma unesterified cholesterol and unesterified/total cholesterol ratio with Aβ Taken together our data indicate that cholesterol esterification is hampered in plasma and CSF of AD patients and that plasma cholesterol esterification biomarkers (unesterified cholesterol and unesterified/total cholesterol ratio) are significantly associated to disease biomarkers (i.e., CSF Aβ
Identifiants
pubmed: 37210544
doi: 10.1186/s13195-023-01241-6
pii: 10.1186/s13195-023-01241-6
pmc: PMC10199596
doi:
Substances chimiques
High-Density Lipoproteins, Pre-beta
0
Cholesterol
97C5T2UQ7J
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
95Investigateurs
Simona Andreoni
(S)
Ildebrando Appollonio
(I)
Fulvio Da Re
(F)
Carlo Ferrarese
(C)
Aristotelis Karantzoulis
(A)
Giulia Negro
(G)
Federico Emanuele Pozzi
(FE)
Giulia Remoli
(G)
Benedetta Storti
(B)
Chiara Paola Zoia
(CP)
Informations de copyright
© 2023. The Author(s).
Références
Turri M, Marchi C, Adorni MP, Calabresi L, Zimetti F. Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(5):159123.
pubmed: 35151900
Kontush A, Lindahl M, Lhomme M, Calabresi L, Chapman MJ, Davidson WS. Structure of HDL: particle subclasses and molecular components. Handb Exp Pharmacol. 2015;224:3–51.
pubmed: 25522985
Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta. 2000;1529(1–3):245–56.
pubmed: 11111093
Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life. 2014;66(9):616–23.
pubmed: 25328986
Husain MA, Laurent B, Plourde M. APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics. Front Neurosci. 2021;15:630502.
pubmed: 33679311
pmcid: 7925634
Nguyen D, Dhanasekaran P, Nickel M, Nakatani R, Saito H, Phillips MC, et al. Molecular basis for the differences in lipid and lipoprotein binding properties of human apolipoproteins E3 and E4. Biochemistry. 2010;49(51):10881–9.
pubmed: 21114327
Hatters DM, Zhong N, Rutenber E, Weisgraber KH. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol. 2006;361(5):932–44.
pubmed: 16890957
Li H, Dhanasekaran P, Alexander ET, Rader DJ, Phillips MC, Lund-Katz S. Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels. Arterioscler Thromb Vasc Biol. 2013;33(4):687–93.
pubmed: 23413428
pmcid: 3660844
Frisoni GB, Calabresi L, Geroldi C, Bianchetti A, D’Acquarica AL, Govoni S, et al. Apolipoprotein E epsilon 4 allele in Alzheimer’s disease and vascular dementia. Dementia. 1994;5(5):240–2.
pubmed: 7951679
Dal Magro R, Simonelli S, Cox A, Formicola B, Corti R, Cassina V, et al. The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the beta-Amyloid Efflux Across the Blood-Brain Barrier in vitro. Front Neurosci. 2019;13:419.
Fernández-de-Retana S, Cano-Sarabia M, Marazuela P, Sánchez-Quesada JL, Garcia-Leon A, Montañola A, et al. Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral beta-amyloidosis. Sci Rep. 2017;7(1):14637.
pubmed: 29116115
pmcid: 5677083
Vance JE, Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta. 2010;1801(8):806–18.
pubmed: 20170744
Marchi C, Adorni MP, Caffarra P, Ronda N, Spallazzi M, Barocco F, et al. ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer’s disease. J Lipid Res. 2019;60(8):1449–56.
pubmed: 31167810
pmcid: 6672040
Yassine HN, Feng Q, Chiang J, Petrosspour LM, Fonteh AN, Chui HC, et al. ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer’s Disease. J Am Heart Assoc. 2016;5(2):e002886.
pubmed: 26873692
pmcid: 4802440
Ko YA, Billheimer JT, Lyssenko NN, Kueider-Paisley A, Wolk DA, Arnold SE, et al. ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):194.
pubmed: 36572909
pmcid: 9791777
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.
pubmed: 21514250
pmcid: 3312024
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539–47.
pubmed: 27371494
pmcid: 4970664
Conti E, Nacinovich R, Bomba M, Raggi ME, Neri F, Ferrarese C, et al. Beta-amyloid plasma levels in adolescents with anorexia nervosa of the restrictive type. Neuropsychobiology. 2015;71(3):154–7.
pubmed: 25998413
Arcaro M, Fenoglio C, Serpente M, Arighi A, Fumagalli GG, Sacchi L, et al. A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1–42 and 1–40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease. Biomedicines. 2022;10(10):2667.
pubmed: 36289929
pmcid: 9599653
Calabresi L, Pisciotta L, Costantin A, Frigerio I, Eberini I, Alessandrini P, et al. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol. 2005;25(9):1972–8.
pubmed: 15994445
Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res. 2005;46(10):2246–53.
pubmed: 16061948
Zimetti F, Weibel GK, Duong M, Rothblat GH. Measurement of cholesterol bidirectional flux between cells and lipoproteins. J Lipid Res. 2006;47(3):605–13.
pubmed: 16327021
Palumbo M, Giammanco A, Purrello F, Pavanello C, Mombelli G, Di Pino A, et al. Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation. Front Mol Biosci. 2022;9:925587.
pubmed: 35928226
pmcid: 9343790
Favari E, Zimetti F, Bortnick AE, Adorni MP, Zanotti I, Canavesi M, et al. Impaired ATP-binding cassette transporter A1-mediated sterol efflux from oxidized LDL-loaded macrophages. FEBS Lett. 2005;579(29):6537–42.
pubmed: 16289478
Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol. 2006;26(3):534–40.
pubmed: 16357317
Vitali C, Wellington CL, Calabresi L. HDL and cholesterol handling in the brain. Cardiovasc Res. 2014;103(3):405–13.
pubmed: 24907980
Papotti B, Adorni MP, Marchi C, Zimetti F, Ronda N, Panighel G, et al. PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer’s Disease. Int J Mol Sci. 2022;23(20):12192.
pubmed: 36293049
pmcid: 9602670
Frisoni GB, Calabresi L, Geroldi C, Bianchetti A, D’Acquarica AL, Govoni S, et al. Apolipoprotein E epsilon 4 allele frequency in vascular dementia and Alzheimer’s disease. Stroke. 1994;25(8):1703–4.
pubmed: 8042228
Frisoni GB, Govoni S, Geroldi C, Bianchetti A, Calabresi L, Franceschini G, et al. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer’s disease. Ann Neurol. 1995;37(5):596–604.
pubmed: 7755354
Endo Y, Fujita M, Ikewaki K. HDL Functions-Current Status and Future Perspectives. Biomolecules. 2023;13(1):105.
pubmed: 36671490
pmcid: 9855960
Bjorkhem I, Leoni V, Meaney S. Genetic connections between neurological disorders and cholesterol metabolism. J Lipid Res. 2010;51(9):2489–503.
pubmed: 20466796
pmcid: 2918434
Pavanello C, Calabresi L. Genetic, biochemical, and clinical features of LCAT deficiency: update for 2020. Curr Opin Lipidol. 2020;31(4):232–7.
pubmed: 32618730
Pavanello C, Ossoli A, Strazzella A, Risè P, Veglia F, Lhomme M, et al. Plasma FA composition in familial LCAT deficiency indicates SOAT2-derived cholesteryl ester formation in humans. J Lipid Res. 2022;63(7):100232.
pubmed: 35598637
pmcid: 9198958
Adorni MP, Ronda N, Bernini F, Zimetti F. High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives. Cells. 2021;10(3):574.
pubmed: 33807918
pmcid: 8002038
Rye KA, Bright R, Psaltis M, Barter PJ. Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E. J Lipid Res. 2006;47(5):1025–36.
pubmed: 16452453
Lennol MP, Sánchez-Domínguez I, Cuchillo-Ibañez I, Camporesi E, Brinkmalm G, Alcolea D, et al. Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients. Alzheimers Res Ther. 2022;14(1):161.
pubmed: 36324176
pmcid: 9628034
Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem. 2012;287(4):2678–88.
pubmed: 22134919
Varesi A, Carrara A, Pires VG, Floris V, Pierella E, Savioli G, et al. Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview. Cells. 2022;11(8):1367.
pubmed: 35456047
pmcid: 9044750
Hawksworth J, Fernández E, Gevaert K. A new generation of AD biomarkers: 2019 to 2021. Ageing Res Rev. 2022;79:101654.
pubmed: 35636691
Wang J, Zhang X, Zhu B, Fu P, On the behalf of Alzheimer’s Disease Neuroimaging Initiative. Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic Degeneration Across the Alzheimer’s Disease Continuum. Neuropsychiatr Dis Treat. 2020;16:183–90.
pubmed: 32021212
pmcid: 6980869
Minta K, Brinkmalm G, Janelidze S, Sjödin S, Portelius E, Stomrud E, et al. Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimers Res Ther. 2020;12(1):19.
pubmed: 32054532
pmcid: 7020540
Zuin M, Cervellati C, Trentini A, Passaro A, Rosta V, Zimetti F, et al. Association between Serum Concentrations of Apolipoprotein A-I (ApoA-I) and Alzheimer’s Disease: Systematic Review and Meta-Analysis. Diagnostics (Basel). 2021;11(6):984.
pubmed: 34071695
Johansson P, Almqvist EG, Bjerke M, Wallin A, Johansson JO, Andreasson U, et al. Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer’s Disease. J Alzheimers Dis. 2017;59(3):1017–26.
pubmed: 28697566
Sodero AO. 24S-hydroxycholesterol: Cellular effects and variations in brain diseases. J Neurochem. 2021;157(4):899–918.
pubmed: 33118626
Schönknecht P, Lütjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, et al. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer’s disease compared to healthy controls. Neurosci Lett. 2002;324(1):83–5.
pubmed: 11983301
Zuliani G, Donnorso MP, Bosi C, Passaro A, Dalla Nora E, Zurlo A, et al. Plasma 24S-hydroxycholesterol levels in elderly subjects with late onset Alzheimer’s disease or vascular dementia: a case-control study. BMC Neurol. 2011;11:121.
pubmed: 21970714
pmcid: 3199239